Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OrbusNeich to validate bioengineered stent

This article was originally published in Clinica

Executive Summary

Just weeks after announcing it had CE-marked for sale in Europe the first bioengineered stent, Genous, Hong Kong firm OrbusNeich is pressing on with its clinical trial programme to substantiate the product's efficacy. The company has begun a global internet-based registry called e-HEALING, which will assess outcomes of 5,000 patients enrolled at over 100 centres; the device is currently only available through the registry. The registry is sufficiently large to generate the data needed to quantify the technology's safety profile, said the company. The company has also completed the design phase of an upcoming randomised trial, called HEALING III, which will involve angiographic follow up to compare Genous stents with bare metal stents both in conjunction with statin therapy. HEALING III is scheduled to start later this year or in early 2006.

You may also be interested in...



Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.

Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.

ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.

Topics

UsernamePublicRestriction

Register

OM013626

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel